INT184980

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.18
Pain Relevance 0.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (NDC80) mitosis (NDC80) chromosome segregation (NDC80)
chromosome (NDC80) nucleus (NDC80) cell cycle (NDC80)
Anatomy Link Frequency
keratinocyte 1
NDC80 (Homo sapiens)
Pain Link Frequency Relevance Heat
psoriasis 3 96.88 Very High Very High Very High
dexamethasone 90 80.92 Quite High
antagonist 12 65.24 Quite High
cytokine 1 51.44 Quite High
corticosteroid 3 22.24 Low Low
withdrawal 3 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
Neurotransmitter 2 5.00 Very Low Very Low Very Low
metalloproteinase 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 25 100.00 Very High Very High Very High
Psoriasis 5 96.88 Very High Very High Very High
Vomiting 31 94.44 High High
Skin Cancer 4 84.92 Quite High
Breast Cancer 2 76.00 Quite High
Obesity 1 56.40 Quite High
Ovarian Cancer 1 45.20 Quite Low
Aging 1 43.44 Quite Low
Apoptosis 8 5.00 Very Low Very Low Very Low
Colon Cancer 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The suppression of SCCA1 has been demonstrated to inhibit tumour growth [22], HEC expression is increased in tumours [23] and S100A9 has been found to be up-regulated in psoriasis patients displaying keratinocyte hyperproliferation and altered differentiation [24].
Gene_expression (expression) of HEC in keratinocyte associated with psoriasis and cancer
1) Confidence 0.67 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1182358 Disease Relevance 0.83 Pain Relevance 0.07
Phase III studies (in both the HEC and MEC settings) also examined the efficacy of a 3-day regimen of casopitant where the day 1 oral dose was replaced by an IV dose of 90 mg casopitant, selected to provide a similar casopitant exposure to the 150 mg oral dose form.
Gene_expression (settings) of HEC
2) Confidence 0.13 Published 2009 Journal Support Care Cancer Section Body Doc Link PMC2726912 Disease Relevance 0.35 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox